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Abstract
The MSRV (multiple sclerosis-associated retrovirus) belongs to the human endogenous retrovirus 
HERV-W family. The envelope protein originating from the MSRV has been found in most patients 
with multiple sclerosis (MS). This protein (Env-ms) has pro-inflammatory properties for several 
types of immune cells and could therefore play a role in MS pathogenesis by promoting the 
leukocyte diapedesis observed in the central nervous system of patients. Our study aims to 
analyze the effects of Env-ms on the blood–brain barrier (BBB) at a molecular and functional level. 
We demonstrate that the recombinant MSRV envelope is able to stimulate several inflammatory 
parameters in a human BBB in vitro model, the HCMEC/D3 brain endothelial cell line. Indeed, 
Env-ms induces over-expression of ICAM-1, a major mediator of leukocyte adhesion to endothelial 
cells, in a dose-dependent manner as well as a strong dose-dependent production of the pro-
inflammatory cytokines IL-6 and IL-8. Furthermore, using a silencing approach with siRNAs, we 
show that Env-ms is recognized via the Toll-like receptor 4 receptor, a pattern recognition receptor 
of innate immunity present on endothelial cells. We also show, using functional assays, that 
treatment of brain endothelial cells with Env-ms significantly stimulated the adhesion and the 
transmigration of activated immune cells through a monolayer of endothelial cells. These findings 
support the hypothesis that MSRV could be involved in the pathogenesis of MS disease or at least 
in maintenance of inflammatory conditions, thus fueling the auto-immune disorder. MSRV could also 
play a role in other chronic inflammatory diseases.
Keywords: auto-immune disease, blood–brain barrier, leukocyte adhesion, retroviral envelope
Introduction
Multiple sclerosis-associated retrovirus (MSRV) is an envel-
oped retrovirus initially isolated from cell cultures from patients 
with multiple sclerosis (MS) (1). It is the first identified mem-
ber of the human endogenous retrovirus W (HERV-W) family 
(2) which has infected the germline and then has been trans-
mitted to the offspring of their hosts in the course of primate 
evolution (3). Most of the integrated HERV-W display dele-
tions or mutations in their open reading frames encoding 
functional proteins (4), thus preventing a complete expres-
sion. However, genetic elements of endogenous HERV are 
involved in genetic rearrangements (5) that can contribute to 
their genetic diversification and their occasional expression (3) 
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which was reported in several diseases [see, for review, (6)]. 
To date, MSRV is the unique example of HERV-W expressed 
as viral particles. Pathological consequences of the exposure 
to MSRV were demonstrated in humanized SCID mice that 
responded by strong pro-inflammatory cytokines, such as 
tumor necrosis factor (TNF)-α, leading to death by brain hem-
orrhages (7). Interestingly, pro-inflammatory and immunopath-
ogenic effects of MSRV are achieved by its envelope protein 
(Env-ms) through the activation of Toll-like receptor (TLR) 4 and 
its CD14 co-receptor (8, 9). Of note, another member of the 
HERV-W family, integrated in the chromosome 7, possesses 
an expressed Env, called syncytin (Env-syn). However, Env-
syn is found only in placenta playing an important role in the 
physiology of syncytiotrophoblast formation (2, 10), whereas 
several studies demonstrate the presence of Env-ms in mac-
rophages or microglial cells in active plaques of all MS brains 
(11, 12). Moreover, Env-ms is found circulating in plasma 
from 73% of patients with MS and not in control donors (11). 
Interestingly, blood circulating Env-ms is also detected among 
some schizophrenic patients in correlation with their level of 
blood C-reactive protein showing a link between Env-ms and 
the systemic inflammation status of the patients (13). The pre-
cise action of MSRV in the pathogenesis of MS remains still 
unclear. For instance, the relative chronology of the expression 
of Env-ms, i.e. in activated monocytes/macrophages of the 
brain versus in the circulating blood, is unknown and difficult, 
even impossible, to assess. Several lines of evidence suggest 
that the Env expression can originate from the trans-activation 
of endogenous sequences belonging to the HERV-W family by 
infectious co-factors such as Epstein–Barr virus which is often 
found in MS patients (11, 14).
MS is an inflammatory demyelinating disease in which 
infiltrating lymphocytes and macrophages are observed 
in the perivascular space of central nervous system (CNS). 
The recruitment of immune cells to areas of demyelination is 
largely conditioned by blood–brain barrier (BBB) integrity and 
by the inflammatory environment [see (15–18) for reviews]. In 
the present study, we measured the pro-inflammatory proper-
ties of two different envelope proteins originating either from 
MSRV (Env-ms) or its endogenous counterpart HERV-W ele-
ment stably inserted into the chromosome 7 (syncytin Env-
syn). We assessed envelope protein effects on human brain 
endothelial cells (HCMEC/D3 cell line) reconstituting an in 
vitro BBB model (19), and on primary human umbilical vein 
endothelial cells (HUVECs). Furthermore, we investigated 
the mechanisms by which each envelope protein interacts 
with endothelial cells. We report that the recombinant MSRV 
envelope protein is able to trigger the secretion of several 
pro-inflammatory cytokines and the over-expression of ICAM-
1, an adhesion molecule involved in key steps of leukocyte 
transendothelial migration, on both HCMEC/D3 and HUVECs. 
We also show that the pattern recognition receptor TLR4 is 
implicated in Env-ms recognition by HCMEC/D3 cells.
Methods
Recombinant proteins
The recombinant Env-ms and Env-syn proteins were 
obtained as previously described (8). Monoclonal antibod-
ies GN-mAb01 and GN-mAb03, detecting both Env-ms and 
Env-syn proteins and GN-mAb12, detecting gag protein, 
were obtained from GeNeuro (Geneva, Switzerland).
Cells and culture conditions
HCMEC/D3 cells were obtained from P. O. Couraud (Institut 
Cochin, Paris, France) and cultured as previously described 
(19). Briefly, cells were seeded onto collagen type 1 (Sigma-
Aldrich, St Louis, MO, USA) coated flasks in supplemented 
EBM-2 medium (Lonza ‘bullet kit’, Basel, Switzerland) con-
taining 2.5% fetal bovine serum (FBS) and growth factors, 
bFGF, VEGF, IGF, EGF at a final concentration 4× lower than 
recommended by the furnisher. Cells were obtained at pas-
sage 26 and cultured up to passage 36.
Primary HUVECs were cultured in M199 medium con-
taining 20% heat-inactivated FBS, ECGS (Endothelial Cells 
Growth Supplement, 50 µg ml−1), heparin (100 µg ml−1) and 
antibiotics. Cells were cultured up to passage 5 onto collagen 
type 1 (Sigma) coated flasks.
HL-60 cells, a human promyelocytic leukemia cell line, was 
cultured in RPMI 1640 containing 10% FBS.
Cell stimulation
HCMEC/D3 or HUVECs were seeded onto collagen type 1 
coated 24-well plates until reaching confluency. Media were 
then replaced with media containing recombinant proteins or 
stimulating cytokines for 16 h. All conditions were tested in 
triplicate. After stimulation, cells were trypsinized and ana-
lyzed by flow cytometry for the expression of ICAM-1 and 
supernatants were collected and frozen at −80°C before anal-
ysis by ELISA for the production of cytokines (IL-6, IL-8 and 
TNF-α detection kits purchased from PromoKine/Promcell, 
Heidelberg, Germany).
Adhesion and transmigration assays
For adhesion assays, HL-60 cells were cultured at a con-
centration of 2.105 cells ml−1 and activated with vitamin D3 
(18.7 µg ml−1) and indomethacin (10−7 M; Sigma-Aldrich) for 
72 h. HL-60 cells were detached with a scraper and labeled 
with calcein AM (Invitrogen Molecular Probes, Carlsbad, CA, 
USA) just before the experiment. Then 1.106 cells were left 
to adhere for 35 min onto a confluent HCMEC/D3 monolayer 
representing a surface of ~3.8 cm2. After three washing steps 
with PBS, the remaining adherent cells were lysed with 1 % 
SDS. For each condition, cell lysate is plotted in triplicate on a 
96-well plate before fluorescence measurement, with a Victor 
3 spectrophotometer (1420 multilabel counter; Perkin Elmer).
For transmigration assays, HCMEC/D3 (2 × 104 per well) were 
grown to confluency onto collagen-coated (100 µg ml−1) porous 
polycarbonate membrane (Transwell, 8-µm pore size, 6.5 mm 
diameter; Costar, Cambridge, MA, USA) for 3–4 days at 37°C 
and stimulated with TNF-α (100 U ml−1) or 2 µg ml−1 of Env-ms for 
18 h prior to the assay. For inhibition experiments, Env-ms (2 µg 
ml−1) was pre-incubated with monoclonal antibodies specific 
for Env-ms or gag protein (30 µg ml−1, 30 min 4°C). Activated 
HL-60 cells (105 cells per well) were added to the upper com-
partment, A  concentration of 2 × 10−8 M fMLP (Calbiochem-
Novabiochem) was added in the lower compartment, to create 
a chemotactic gradient for peripheral mono nuclear cells. After 
1 h at 37°C, migrated HL-60 cells were recovered from the 
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bottom well, centrifuged and quantified using a CyQUANT 
assay kit (Molecular Probes, Eugene, OR, USA).
Immunostaining for flow cytometry
After trypsinization, living cells were incubated for 1 h at 4°C 
with anti-ICAM-1 primary antibody (clone 2D5 produced 
locally as previously described) (20). After centrifugation, pel-
lets were re-suspended in 50 µl of RPMI 1640 containing the 
secondary antibody coupled with FITC (goat anti-mouse-FITC 
purchased from Jackson ImmunoResearch, Philadelphia, PA, 
USA) and left to incubate for 30 min at 4°C. After centrifuga-
tion, cells were re-suspended in 500 µl of RPMI 1640 + 10% 
FBS and fluorescence was measured with a FACSCAN flow 
cytometer (Becton Dickinson, Le Pont-De-Claix, France). 
Results were analyzed using WinMDI software.
Immunostaining for fluorescence microscopy
Cells were seeded onto LabTek chambers (Nunc, Rochester, 
NY, USA) until confluence and were then stimulated for 
16 h in the chambers. Cells were then washed twice with 
pre-warmed (37°C) PBS containing Ca++ and Mg++ and 
then fixed for 30 min at room temperature with PBS Ca-Mg 
containing 2% PFA and 2% sucrose. After fixation, we per-
formed two quenching steps with PBS containing glycine 
0.1 M and NaN3 0.01% for 10 min and a permeabilization 
step using PBS containing 0.2% saponin, 2% BSA, for 
20 min at room temperature. Staining was performed using 
the anti-ICAM-1 primary antibody clone 2D5 with a second-
ary goat anti-mouse antibody coupled to TRITC (Jackson 
ImmunoResearch); anti-TLR4 (Santa Cruz, Santa Cruz, 
CA, USA) with a secondary goat anti-rabbit antibody cou-
pled to Alexa 488; or the anti-golgin 97 (Invitrogen) with a 
secondary goat anti-mouse antibody coupled with Alexa 
555. Nuclei were labeled with Hoechst 33342. Cells were 
observed with an epi-fluorescence microscope (Carl Zeiss 
AxioImager) with the pseudo-confocal module APOTOME. 
Images were analyzed with ImageJ software (ImageJ, NIH, 
USA). For co-localization experiments, the Pearson’s correla-
tion coefficient (Rr) and the Mander’s overlap coefficient (R) 
were calculated using the ImageJ co-localization plugin after 
background subtraction.
Western blotting
After reaching confluence, HCMEC/D3 cells were trypsinized 
and lysed for 30 min on ice with a Tris–HCl 50 mM, pH 7.5, 
NaCl 150 mM buffer containing 1% NP40 or 0.1% SDS (as 
mentioned in each case) and a protease inhibitor cocktail 
(Sigma-Aldrich). Whole cell extracts were submitted to SDS–
PAGE (10% acrylamide gels), blotted onto polyvinylidene 
difluoride membranes and stained with a rabbit polyclonal 
primary antibody raised against TLR4 (Santa Cruz) or actin 
(Sigma-Aldrich) and a secondary goat anti-rabbit antibody 
coupled with peroxidase (Invitrogen). Bands were quantified 
with BioRad Image Lab software.
Treatment with peptide N-glycosidase
Before analysis by western blotting, some extracts were 
treated by peptide N-glycosidase (PNGase) using a 
deglycosylation kit (Sigma, GlycoProfile II, Enzymatic 
In-solution N-Deglycosylation kit). Extracts were treated 
according to the furnisher’s recommendations but omitting 
the denaturation step before adding the PNGase to avoid pre-
cipitation of the proteins. Briefly, 50 µg of extracts were treated 
with 2.5 units of PNGase or water as a negative control for 2 h 
at 37°C, then immediately analyzed by western blotting.
siRNA transfections
siRNA targeting TLR4 were transfected according to the 
manufacturer’s recommendations (Invitrogen). Briefly, we 
transfected the cells with a set of three siRNAs targeting TLR4 
or with a negative control at a final concentration of 20 nM 
(Stealth RNAi all provided by Invitrogen) using Lipofectamine 
RNAiMAX (Invitrogen) when cells reached 30% confluency. 
Cells were re-transfected 48 h later under the same condi-
tions. Forty-eight hours later, the transfected and control cells 
were treated with Env-ms or LPS and then analyzed.
Statistics
All results are expressed as mean ± SE. Data were analyzed 
using R statistical software; two-sided Student t-test was 
used. Differences between conditions were considered sig-
nificant at P <0.05.
Results
Effects of Env-ms on HCMEC/D3 brain endothelial cells
First, we analyzed the effect of Env-ms on confluent mon-
olayers of HCMEC/D3 cells. We observed by fluorescence 
microscopy an increase in expression of ICAM-1 adhesion 
molecules (Fig. 1A). In order to quantify ICAM-1 expression, 
cells were analyzed by flow cytometry for surface expres-
sion of ICAM-1 after incubation with TNF-α, which is known 
to activate endothelial cells, or with Env-ms; both treatments 
induced a strong ICAM-1 expression (Fig. 1B). The induction 
of ICAM-1 expression was specific for Env-ms, since treat-
ment with Env-syn had no significant effect and was dose 
dependent on the ENv-ms concentration (Fig. 1C). To further 
confirm the specificity of Env-ms pro-inflammatory proper-
ties, we pre-incubated Env-ms with monoclonal antibod-
ies recognizing either Env-ms, or the gag protein of HERV 
as a negative control, before treating HCMEC/D3 cells. 
After overnight incubation with the treated Env-ms, ICAM-1 
surface expression by HCMED/D3 cells was measured by 
flow cytometry as detailed above. Anti-Env-ms antibodies 
blocked ~40% of Env-ms-induced ICAM-1 expression as 
compared to the irrelevant anti-gag antibodies (Fig. 1D). We 
performed a complementary control to ensure that there is 
no LPS contamination in the recombinant envelope protein. 
For that purpose, we used polymyxin B (PB) antibiotic that 
can neutralize LPS activity. LPS or Env-ms were pretreated 
or not with PB and then incubated overnight with HCMEC/
D3 cells. The pre-treatment with PB almost completely abol-
ished the LPS-induced ICAM-1 increased expression but had 
no effect on Env-ms-induced ICAM-1 expression, indicating 
that Env-ms pro-inflammatory activity was not caused by LPS 
contamination (Fig. 1E).
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We investigated the effects of Env-ms at a functional level 
by measuring the adhesion between activated immune cells 
and a monolayer of HCMEC/D3 cells. For that purpose, we 
used activated calcein-labeled HL-60 cells adhering to the 
HCMEC/D3 monolayer. After several washing steps and lysis 
of all remaining adherent cells, we quantitated adherence 
of HL-60 cells by fluorescence readings. We observed an 
increase of adherent HL-60 cells when HCMEC D/3 cells had 
previously been treated with Env-ms (Fig. 1F). This increase 
was even stronger than the positive control with LPS treat-
ment, but this was not statistically significant. These results 
are consistent with our observations (Fig.  1A and B) of 
increased expression of ICAM-1 following Env-ms treatment, 
since ICAM-1 is a major mediator of the adhesion between 
activated immune cells and endothelial cells [(20, 21), see 
(22) for review].
Adhesion of leukocytes to the endothelium can be followed 
by leukocyte transendothelial migration. As shown in Fig. 1 
(G), Env-ms was able to stimulate transendothelial migration 
of HL-60 cells; this increased transmigration was inhibited (by 
80%) when Env-ms was pre-incubated with a specific mono-
clonal antibody (GN-mAb03), while an antibody specific for 
Gag protein was devoid of any inhibitory effect.
Recombinant Env-ms induced a strong and dose-depend-
ent production of IL-6 (Fig. 2A) and IL-8 (Fig. 2B) but did not 
induce significant production of TNF-α (data not shown). The 
induction of these pro-inflammatory cytokines is specific of 
Env-ms since Env-syn had no effect.
Taken together, these results indicate that Env-ms exerts a 
specific pro-inflammatory activity on brain endothelial cells.
Effects of Env-ms on primary endothelial cells
The effects of Env-ms were further studied on primary 
HUVEC. Recombinant Env-ms induced an increased expres-
sion of ICAM-1 (Fig. 3A) similar to that observed previously 
with HCMEC/D3 cells. Furthermore, HUVECs responded 
to Env-ms by a strong dose-dependent production of IL-8 
(Fig. 3C). In contrast, no significant production of IL-6 was 
obtained after incubation of HUVECs with either Env-ms 
or TNF-α (Fig.  3B). However, primary HUVECs are able to 
Fig. 1. Env-ms specifically induces over-expression of ICAM-1 on HCMEC/D3 cells but not Env-syn. (A) Indirect immunostaining of ICAM-1 (red) 
on untreated HCMEC/D3 cells or after overnight treatment with Env-ms at 2 µg ml−1. Nuclei are stained in blue. Scale bar: 20 µm. (B and C). Flow 
cytometry analysis of ICAM-1 expression after overnight treatment of HCMEC/D3 cells (B) with TNF-α (100 U ml−1) or Env-ms (2 µg ml−1) (NT: not 
treated) and (C) with TNF-α (100 U ml−1), Env-ms or Env-syn. Values are means ± SE of fluorescence intensity in two independent experiments 
each performed in duplicate. Negative control: an irrelevant antibody of the same isotype (IgG1) as the monoclonal antibody specific for ICAM-
1. (D) Inhibition using monoclonal antibodies. HCMEC/D3 cells were stimulated overnight with Env-ms (2 µg ml−1) pre-incubated for 40 min at 
4°C with mAbs (30 µg ml−1) specific for Env-ms (GN-mAb03) or gag (GN-mAb12) proteins. ICAM-1 expression was then measured by flow 
cytometry. Results represent the mean of the fold of increase (ratio between mean of fluorescence of the activated cells and untreated cells) ± 
SE of three independent experiments. (E) PB inhibition assay: HCMEC/D3 cells were treated overnight with Env-ms (2 µg ml−1) or LPS (0.1 µg 
ml−1), pre-incubated or not for 30 min at 37°C with PB (25 µg ml−1). ICAM-1 expression was measured by flow cytometry (see above). Results 
represent the mean ± SE of two independent experiments. (F) Env-ms stimulates the adhesion between immune cells and the endothelial mon-
olayer. Results represent means of fold of increase compared to untreated condition ± SE of two independent experiments each performed in 
triplicate. (G) Env-ms (2 µg ml−1) stimulates the transmigration of HL-60 cells through the endothelial monolayer. TNF (100 U ml−1) was used as 
a positive control for transmigration. Results represent means of fold of increase compared to untreated condition ± SE of three independent 
experiments each performed in duplicate. *P ≤ 0.05; **P ≤ 0.01.
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produce IL-6 in response to LPS stimulation (Fig. 3B). Taken 
together, these results indicate that Env-ms also induces a 
pro-inflammatory response of HUVECs but with a slightly dif-
ferent cytokine profile than that of HCMEC/D3 cells.
Implication of TLR4 in Env-ms recognition by 
endothelial cells
TLR4 is expressed by HCMEC/D3. It has been previously 
shown that Env-ms interacts with the receptor of innate immunity 
TLR4/CD14, on monocytes and dendritic cells (8); therefore, we 
investigated whether this pathway may be used by endothe-
lial cells to respond to ENV-ms. TLR4 expression was analyzed 
in permeabilized HCMEC/D3 cells by fluorescent microscopy 
which showed that TLR4 mostly co-localized with the Golgi 
apparatus (Fig. 4A) as has been previously described in other 
cell types (23, 24). Analysis by western blotting demonstrated 
that in both HCMEC/D3 and HUVECs, TLR4 was expressed as 
a 150 kDa protein, with a minor band at 120 kDa (Fig. 4B). It 
has been reported in the literature that the heavy form is the 
fully processed, glycosylated and active form which can be 
expressed at the cell membrane, while the light form remains 
intracellular (25). These observations suggest that a fully gly-
cosylated TLR4 form could be expressed by the HCMEC/D3 
cells. Treatment of the whole cell extracts with PNGase resulted 
in the disappearance of the heavy form in favor of the light form 
(Fig. 4C), showing that the heavy form is glycosylated.
TLR4 knock down abolishes HCMEC/D3 response to 
Env-ms. Subsequently, in order to verify that TLR4 is the 
receptor implicated in Env-ms recognition, we transfected 
HCMEC/D3 cells with TLR4-targeting siRNAS and assessed 
the efficiency of TLR4 knock down by western blotting 
(Fig.  4D). After quantification with ImageJ, we measured a 
44% decrease of TLR4 expression after two rounds of trans-
fection with TLR4-targeting siRNA when compared to control 
siRNA-transfected cells and a 59% decrease compared to 
untransfected cells.
We then analyzed the effect of reduced TLR4 expression 
on the induction of ICAM-1 expression and on the produc-
tion of pro-inflammatory cytokines by LPS, a well-known 
Fig. 2. Env-ms, but not Env-syn, induces a dose-dependant produc-
tion of IL-6 and IL-8. (A) Analysis of IL-6 production by HCMEC/D3 
cells. Cells were treated overnight with TNF-α, Env-ms or Env-syn, 
then IL-6 was measured in the supernatants of the culture by ELISA. 
Results represent the mean ± SE of two independent experiments 
each performed in duplicate. (B) Analysis of IL-8 production by 
HCMEC/D3 cells. Same conditions as for IL-6 measurements. *P ≤ 
0.05; **P ≤ 0.01.
Fig. 3. Env-ms has significant, but different effects on HUVECs, com-
pared to HCMEC/D3 cells. (A) Flow cytometry analysis of ICAM-1 
expression after overnight treatment of HUVECs with TNF-α, Env-ms 
or Env-syn. (B) Analysis of IL-6 production by HUVECs. Cells were 
treated overnight with TNF-α, Env-ms or Env-syn, IL-6 was measured 
with ELISA. (C) Analysis of IL-8 production by HUVECs. Same condi-
tions as for IL-6 measurements. Results represent the mean ± SE of 
2–4 independent experiments each performed in triplicate. *P ≤ 0.05; 
**P ≤ 0.001.
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TLR4 ligand, or by Env-ms (Fig. 5). The results showed that 
ICAM-1 expression, induced by either LPS or Env-ms, was 
significantly reduced (by at least half) in knocked down 
cells compared to the cells transfected with a control siRNA 
(Fig. 5A). The specificity of TLR4 silencing by these siRNAs 
is shown in Fig.  5(B), which shows that TNF-α is still able 
to induce the expression of ICAM-1 after transfection with 
these siRNAs. Furthermore, the production of IL-6 and IL-8 
cytokines induced by either LPS or Env-ms was dramatically 
decreased (by ~90%) after TLR4 knock down as compared 
to control transfected cells (Fig. 5C and D). Taken together, 
these results support the hypothesis that TLR4 is implicated 
in Env-ms recognition by HCMEC/D3 cells.
Discussion
MS is a chronic neurological disease, whose etiology remains 
poorly defined. However, it is well established that inflamma-
tory process in the brain yields to the destruction of oligo-
dendrocytes which build myelin sheaths around axons in the 
brain and spinal cord (26). Under inflammatory conditions, 
vascular endothelial cells respond by the secretion of fac-
tors and the increase of adhesion molecules that lead to an 
enhancement of leukocyte adhesiveness and to their migra-
tion into tissues (27). The recruitment of activated leukocytes 
across BBB endothelial cells is a critical step in triggering 
inflammation and CNS tissue injury in the course of MS (18). 
Therefore, the initiation of the inflammatory process, along 
with its outcome on the neuroimmunological context, remains 
a central point of interest in the understanding of MS.
The discovery of the retroviral element MSRV, isolated from 
the cerebrospinal fluid of a patient with MS (1), has opened 
new issues about a putative microbial contribution in MS 
physiopathology, reviewed in (6). Several lines of evidence 
indicate that MSRV could participate to the activation of some 
immune cells. MSRV and its envelope protein, Env-ms, trig-
ger T-cell receptor Vβ (28) and TLR4 (8), similarly to supe-
rantigens such as those encoded by mouse mammary tumor 
virus (29, 30).
Since Env-ms could activate innate immunity through the 
TLR4/CD14 pathway, we further sought pro-inflammatory 
activity on endothelial cells which are known to express TLR 
and respond to TLR signals (27, 31). Indeed, we demon-
strate that Env-ms is able to activate the vascular endothe-
lium including the brain endothelium in a manner consistent 
with the fact that MS is an inflammatory disease of the CNS. 
Regarding the activation pathways, our results show that 
the inhibition of Env-ms induced pro-inflammatory effects 
is incomplete after TLR4 knock down. This most probably 
arises from the fact that TLR4 expression is not completely 
abolished after transfection with siRNAs as observed on our 
western blotting experiment (Fig. 5D). Nevertheless, we can-
not exclude the implication of TLR4 co-receptor CD14 (32). 
Indeed, although CD14 is not detected in HCMED/D3 cells by 
western blotting, it is known to be present in serum (33, 34). 
In our model, it would be difficult to perform experiments with 
serum depletion since HCMEC/D3 cells are very sensitive to 
any modification of culture medium, therefore no definitive 
conclusion concerning the role of CD14 can be drawn.
One interesting observation of our study concerns the dif-
ferent effects of Env-ms in endothelial cells of different ori-
gins. The envelope protein seems to exert a slightly higher 
pro-inflammatory activity on HCMEC/D3 cells that originate 
Fig. 4. TLR4 expression in endothelial cells. (A) TLR4 co-localizes 
with the Golgi apparatus. Fluorescent staining of Golgi apparatus 
(red), TLR4 (green) and nuclei (blue) on HCMEC/D3 cells (not con-
fluent) after fixation with PFA 2% and permeabilization with saponin 
0.2%. Negative control is obtained after staining with the second-
ary antibodies only. Pearson’s correlation coefficient Rr = 0.67 and 
Mander’s overlap coefficient R = 0.75. Scale bar: 20 µm. (B) TLR4 is 
expressed on HCMEC/D3 and on HUVECs. Cells were lysed with the 
Tris–HCl 50 mM, pH 7.5, NaCl 150 mM buffer containing 1% NP40. 
The presence of TLR4 in the whole extracts is then analyzed by 
western blotting. (C) TLR4 heavy form (150 kDa) leads to a light form 
(120 kDa) after treatment with PNGase. Whole extracts, prepared 
with a lysis buffer containing only NP40, were treated with PNGase, 
or water as a negative control, for 2 h and then analyzed by west-
ern blotting. (D) TLR4 expression on HCMEC/D3 cells after double 
transfection with siRNAs targeting TLR4 or control siRNAs; cells were 
lysed with the Tris–HCl 50 mM, pH 7.5, NaCl 150 mM buffer contain-
ing 1% NP40. The presence of TLR4 in the whole extracts was then 
analyzed by western blotting and quantified with ImageJ software. 
NT: not transfected.
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from the brain than on HUVECs that originate from umbilical 
vein. Indeed, Env-ms triggers the over-expression of ICAM-1 
and the production of IL-6 and IL-8 by HCMEC/D3 while only 
ICAM-1 expression and IL-8 production are strongly stimu-
lated on HUVEC. This is not due to differences in the levels 
of TLR4 expression between HCMEC and HUVECs since 
we verified by western blotting that TLR4 was expressed at 
a similar level in both cell types (Fig.  4B). Concerning the 
cytokine production, HUVECs are known to produce a much 
lower amount of IL-6 compared to IL-8 in response to LPS and 
their response to TNF-α is controversial and depends on cul-
ture conditions as already discussed by Makó et al. (35). That 
could explain the absence of IL-6 production after treatment 
with Env-ms and TNF-α. However, in our conditions, HUVECs 
are able to produce significant amounts of IL-6 in response 
to LPS but not in response to Env-ms (Fig. 3C). These varia-
tions observed between LPS and Env-ms effects on HUVECs 
could be explained by a lower affinity of the latter with TLR4 
possibly due to structural differences. Finally, in spite of these 
variations, we show that Env-ms exerts its pro-inflammatory 
activity on both types of vascular endothelial cells.
The presence of Env-ms protein was detected in the periph-
eral blood of most of MS patients as a soluble protein in the 
serum and as a membrane-associated protein at the surface 
of circulating monocytes and to a lesser extend on B and 
NK cells (14). Histology of brain tissues of some postmor-
tem MS patients revealed that perivascular lesions contained 
a large number of macrophages and microglial cells which 
expressed Env protein as well as HLA-DR (11). Whatever the 
initial origin of Env-ms, either at the periphery or in the CNS, 
its presence in both compartments may contribute establish-
ing conditions for neuro-inflammatory damage. This is further 
strengthened by the fact that human oligodendrocyte differ-
entiation is impaired after exposure to Env-ms leading to the 
reduction in expression of myelin protein (36). It is striking to 
note that again in this latter case, Env-ms triggers TLR4 path-
way in oligodendroglial precursor cells which respond by the 
production of pro-inflammatory cytokines and reactive oxy-
gen species. Interestingly, TLR4 is expressed by other cells 
contributing to the BBB formation. Firstly, astrocytes have 
TLR4 but their capacity to respond to its ligands has been a 
subject of debates. Recently, it has been shown that astrocyte 
response to LPS stimulation requires CD14 expression (37). 
Secondly, pericytes, which surround endothelial cells to build 
capillaries, possess a functional TLR4 that responds to LPS 
stimulation by the production of pro-inflammatory cytokines 
and up-regulation of ICAM-1 (38). Although the reactivity of 
pericytes and astrocytes to an Env-ms signal remains to be 
firmly established, one may consider that the convergence 
in the BBB of cells expressing TLR4 may favor the particular 
Fig. 5. Effects of Env-ms are greatly impaired after knock down of TLR4 receptor. (A) siRNA-transfected HCMEC/D3 cells were stimulated 
overnight with LPS or Env-ms. ICAM-1 expression was measured by flow cytometry. Cells were either not transfected with siRNA (NT) and not 
stimulated with LPS or Env-ms (untreated), or transfected with control siRNA (CT siRNA) or TLR4 siRNA and stimulated with Env-me (2µg ml−1) or 
LPS (0.1 µg ml−1). Results represent the mean ± SE of three independent experiments each performed in triplicate. (B) Same as in (A): untrans-
fected cells (NT) or cells transfected with TLR4 siRNA were stimulated with TNFα (100 U ml−1, 18 h). (C, D) HCMEC/D3 cells were transfected 
and then stimulated overnight with LPS or Env-ms. Production of IL-6 and IL-8 was measured by ELISA assays. Results represent the mean ± 
SE of two independent experiments each performed in triplicate. NT: not transfected, CT: control. *P ≤ 0.01; **P ≤ 0.001.
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sensitivity of the CNS to the exposure of TLR4 ligands induc-
ing synergic paracrine signals.
Altogether, these data highlight the importance of the 
Env-ms/TLR4 pathway in the demyelination and in the inflam-
mation associated with MS (Fig. 6). In the blood, Env-ms can 
activate on the one hand circulating monocytes, dendritic 
cells and macrophages and on the other hand vascular 
endothelial cells leading to the production of pro-inflamma-
tory cytokines, the enhancement of the adhesion of circulat-
ing cells to endothelium and then their migration through the 
BBB into the brain. Env-ms in the brain provokes activation 
of macrophages, microglial and dendritic cells which orient 
the Th1 response of T lymphocytes. In parallel, Env-ms inter-
feres with oligodendrocyte cells in activating their precur-
sors to produce pro-inflammatory cytokines and in reducing 
their capacity to build myelin sheaths. Simultaneous inflam-
matory conditions together with a myelinization defect may 
favor the rise of myelin-specific Th1 T lymphocytes leading 
to auto-immunity. Obviously, interfering with the Env-ms/TLR4 
pathway represents a promising therapeutic approach which 
is currently progressing by the mean of specific anti-Env-ms 
neutralizing antibodies (39).
In conclusion, our study brings new evidence about the pro-
inflammatory properties of MSRV envelope protein, defines 
the mechanism by which Env-ms stimulates endothelial cells 
and reinforces the proposal that MSRV may play a key role in 
MS pathogenesis and probably in other neurodegenerative 
disorders, such as schizophrenia (13, 40).
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